Jonathan C. Javitt, CEO and Chairman of NRX Pharmaceuticals, Inc., filed a Form 4 on November 4, 2026, disclosing the acquisition of 150,000 restricted stock units granted on July 28, 2026.

Key Highlights

  • Grant date: The RSUs were granted on July 28, 2026, under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended.
  • Grant size: 150,000 restricted stock units were acquired, each representing a contingent right to receive one share of common stock at vesting for no consideration.
  • Price: The price of the derivative security is listed as $0.
  • Vesting schedule: The RSUs vest in three equal annual installments on July 28, 2027, July 28, 2028, and July 28, 2029, subject to continued service through each vesting date.
  • Resulting ownership: Following the transaction, Javitt beneficially owns 150,000 derivative securities directly.
  • Reporting person role: Jonathan C. Javitt is identified as a Director, Officer, and CEO and Chairman of NRX Pharmaceuticals, Inc.

Javitt RSU Grant Details: July 2026 Award Under 2021 Omnibus Incentive Plan

According to the filing, Jonathan C. Javitt, serving as CEO and Chairman of NRX Pharmaceuticals, Inc. (NASDAQ:NRXP), was granted 150,000 restricted stock units on July 28, 2026. The filing classifies the transaction under Table II as an acquisition (transaction code A) of derivative securities. The price of the derivative security is recorded as $0, consistent with the filing's explanation that each RSU represents a contingent right to receive one share of common stock at vesting "for no consideration."

The filing states that the RSUs were granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended. Per the filing's explanation of responses, the units vest "in three equal annual installments on July 28, 2027, July 28, 2028 and July 28, 2029, subject to the reporting person's continued service through each vesting date." The filing reports that Javitt's beneficial ownership of derivative securities following the transaction is 150,000, held directly.

No transactions were reported in Table I covering non-derivative securities. The Form 4 was filed by one reporting person and was not indicated as an amendment to a prior filing. The filing was signed by Jonathan Javitt and dated November 4, 2026.

What Was Disclosed

The filing disclosed a grant of 150,000 RSUs to CEO and Chairman Jonathan C. Javitt on July 28, 2026, under NRX Pharmaceuticals' 2021 Omnibus Incentive Plan, with vesting across three equal annual installments from 2027 through 2029.